Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — Sequent Scientific — Jefferies Healthcare Conference, London 2014
24 slides from Viyash Scientific's conference presentation, November 2014
Slide 1: Company Presentation
Company Presentation Jefferies Healthcare Conference, London November 2014
Slide 2: Important Disclosure
Important Disclosure Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 3: Agenda
Agenda Introduction to Sequent Animal health - an attractive opportunity Well positioned to capitalise on the global animal health opportunity Presence in niche human API Well invested operational and manufacturing infrastructure 3
Slide 4: Introduction to Sequent
Introduction to Sequent Revenue Split Established in 2002 by the promoters of Strides Arcolab and listed on the Bombay Stock Exchange (BSE) in India with market capitalisation of By Geography c.$200 million as on 14-Nov-2014 Integrated pharmaceutical company operating in the domains of Animal RoW US
Slide 5: Sequent – the journey so far…
Sequent – the journey so far… 2005 2012 2014 - onwards Formed as an amalgamation of Re-focused strategy from multiple companies ‘Growth’ to ‘Value’ Equity infusion commitment from Promoters of $40 million of which $25 million has been infused with PI Drugs Transchem balance to come in early 2015 Ani
Slide 6: Evolution of new strategy has begun
Evolution of new strategy has begun Evolution of business strategy from Translating into ‘Top 10’ Global Animal Health ‘Growth’ to ‘Value’ Company by 2018 Initial Strategy – ‘Sweating of Assets’ 250 + ($ million) Aggressive growth strategies for each 83 + business vertical Leveraging long-standing c
Slide 7: Wide range of product portfolio and pipeline
Wide range of product portfolio and pipeline Alivira – Animal Health Human Formulations API API Strategic focus on food producing Leading position in anthelmintics Portfolio of several niche high animals value, low volume APIs across anti- Current portfolio of 19 products with malarial, anthelmintic
Slide 8: Agenda
Agenda Introduction to Sequent Animal health – an attractive opportunity Well positioned to capitalise on the global animal health opportunity Presence in niche human API Well invested operational and manufacturing infrastructure 8
Slide 9: Animal health - an attractive opportunity
Animal health - an attractive opportunity Market size ($ billion) Market by therapeutic area 2012 Market size breakdown 2005-12 CAGR (%) 6% 22.0 22.5 12% 20.1 20% 19.2 18.6 8% 17.9 16.1 14.9 6% 5% 4% 3% 25% 28% 15% Feed Biologicals Anti-Infectives 2005 2006 2007 2008 2009 2010 2011 2012 Parasiticide
Slide 10: Animal health - strong growth drivers
Animal health - strong growth drivers Food Animals Companion Animals Global population growth Growing middleclass & Urbanization, particularly in Emerging markets Increased demand for animal protein Increased pet ownership Productivity improvements Increased medicalisation of pets Heightened focus o
Slide 11: Attractive industry dynamics
Attractive industry dynamics Consolidated market Top 10 companies account for 60% of global market Distinct Product Portfolio Non over lapping product portfolio of ‘Top 10’ companies Self-pay nature of the business, no pressure of payors like insurance companies Limited Pricing or Government Pressur
Slide 12: Agenda
Agenda Introduction to Sequent Animal health - an attractive opportunity Well positioned to capitalise on the global animal health opportunity Presence in niche human API Well invested operational and manufacturing infrastructure 12
Slide 13: Strategic steps towards becoming a leading player in global animal health business
Strategic steps towards becoming a leading player in global animal health business Formulations Formulations B2C model in select Regulated markets Expand B2C model in API additional Emerging Build-up Regulated markets market business built on platform of best in class compliance Several key actions
Slide 14: API – India's largest producer of Animal Health APIs
API – India's largest producer of Animal Health APIs Overview Offers a wide range of products in Anthelmintics; ranks amongst the world’s largest producer of Anthelmintics Expanding portfolio into newer segments like NSAIDS, Beta Agonist, Feed Additives & Ecto-Parasiticides to leverage current relat
Slide 15: API – Manufacturing capabilities being significantly enhanced
API – Manufacturing capabilities being significantly enhanced Joint Venture with Shasun Pharmaceuticals Limited New world class API facility at Visakhapatnam Recent Joint Venture with Shasun to develop, manufacture and sell veterinary products – Shasun brings in its state of the art new large manufa
Slide 16: API – Vizag plant will help scale up business with top global animal health companies
API – Vizag plant will help scale up business with top global animal health companies Global Top 10 Zoetis Albendazole supply since last 4 years On going discussions to supply 3 more products Merck 2 products being supplied for past 12 years Ongoing discussion for 6 more products Elanco On going dis
Slide 17: Formulations – Provet acquisition provides a strategic growth platform
Formulations – Provet acquisition provides a strategic growth platform Overview Beta-Lactam injectable suspension Ranked among top-5 companies in in highly attractive Non-Beta Lactam injectable solution Turkish veterinary market with an estimated market size of $400m and estimated to grow at CAGR of
Slide 18: Formulations – Focus on aggressive growth built on market & portfolio expansion
Formulations – Focus on aggressive growth built on market & portfolio expansion Overview Growth Strategy Forayed into the formulation exports as a forward integration for animal Entry into select high growth markets through health APIs in 2006 acquisition of local company Sales made through distribu
Slide 19: Agenda
Agenda Introduction to Sequent Animal health - an attractive opportunity Well positioned to capitalise on the global animal health opportunity Presence in niche human API Well invested operational and manufacturing infrastructure 19
Slide 20: Presence in niche human API
Presence in niche human API Overview Key capabilities Integrated, multipurpose, API and API Multipurpose design intermediates manufacturing facility located in Mangalore, Karnataka Integrated intermediate production block capable of fully meeting API Intermediates Investments made to enhance product
Slide 21: Agenda
Agenda Introduction to Sequent Animal health - an attractive opportunity Well positioned to capitalise on the global animal health opportunity Presence in niche human API Well invested operational and manufacturing infrastructure 21
Slide 22: Well-invested manufacturing facilities in India and Turkey
Well- Well-invested manufacturing facilities in India and Turkey Manufacturing facilities Ankara, TURKEY equipped to handle a Animal Health Formulations (Strong range of formulations focus on injectables) including injectable Animal Health suspensions, granules for EU-GMP compliant facility Formulat
Slide 23: State-of-the-art dedicated research center in Mangalore
State- State-of- of-the- the-art dedicated research center in Mangalore 80 scientists; including 11 PhDs and 35 Masters in Science 8 world-class labs of 70-75 sq.mt. each and accommodating 80 fume hoods Ability to handle a wide range of reactions in synthetic chemistry Strong expertise in carbohydra
Slide 24: Sequent is well positioned to capitalise on the global animal health opportunity
Sequent is well positioned to capitalise on the global animal health opportunity Market Characteristics SeQuent Advantage Limited competitive intensity from India Only credible Indian player with critical mass in the space Partnerships critical for Long, established relationships with Big Pharma and
Sequent Scientific — Jefferies Healthcare Conference, London 2014 on 6ix